European Commission takes decision.
For drug launch in the United States.
Hungary's leading pharma company reacts.
Recommendations for Esmya approved by CHMP.
To HUF 5,470 from HUF 5,695.
Esmya may remain on markets but with restrictions.
After release of Q1 earnings report.
Analysts are split over after-tax profit.
Share price on the rise.
Annual General Meeting is coming up.
Richter awarded for Cariprazine.
European Medicines Agency is not a bearer of bad news only.
August is the new date.
Slashes target price, removes Esmya from model.
Negative impact on 2017 profits.
Jefferies comment EMA probe, Q4 results.
Profit of Hungary's leading drugs maker plunges.
Sentiment to be impacted by cautionary measures.